Rolipram suppresses tau phosphorylation in 11-month-old 3xTg-AD mice [22] and in the rTg4510 mouse model of frontotemporal dementia at 3–4 months of age [84], but no work has been published on the effects of PDE4B subtype-specific inhibition on tau pathology. This evidence concerns the gene MAPT and Alzheimer disease.